Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: A longitudinal study

Pediatric Blood and Cancer

Volumn 60, Issue 5, 2013, Pages 842-848

  Brown, Tanya Renae ^a   Vijarnsorn, Chodchanok ^a   Potts, Jim ^a   Milner, Ruth ^b   Sandor, George G S ^a   Fryer, Christopher ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anthracycline; Cardiotoxicity; CTCAE; Ewing sarcoma; Pediatrics

Indexed keywords

ANTHRACYCLINE; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; VINCRISTINE;

ADOLESCENT; ARTICLE; AUTOTRANSPLANTATION; BODY MASS; BONE METASTASIS; CANADA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DETERIORATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECHOCARDIOGRAPHY; EWING SARCOMA; FEMALE; HEART DEATH; HEART EJECTION FRACTION; HEART FUNCTION; HEART TRANSPLANTATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; WHOLE BODY RADIATION;

ADOLESCENT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARDIOTOXINS; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASES; HEART FUNCTION TESTS; HUMANS; LONGITUDINAL STUDIES; MALE; RETROSPECTIVE STUDIES; SARCOMA, EWING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84874988636     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24404     Document Type: Article

References (39)

1. Nesbitt ME, Jr., Gehan EA, Burgert EO, Jr., et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study. J Clin Oncol 1990;8:1664-1674.
2. Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990;66:887-893.
3. Oberlin O, Habrand JL, Zucker JM, et al. No benefit of ifosfamide in Ewing's sarcoma: A nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:1407-1412.
4. Wexler LH, DeLaney TF, Tsokos M, et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 1996;78:901-911.
5. Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: Evaluation of combination ifosfamide and etoposide-a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004;22:2873-2876.
6. Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006;47:22-29.
7. Kakadekar AP, Sandor GGS, Fryer C, et al. Differences in dose scheduling as a factor in the etiology of anthracycline induced cardiotoxicity in Ewing sarcoma patients. Med Pediatr Oncol 1997;28:22-26.
8. Hossain A, Chen A, Ivy P, et al. The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: Updating the common terminology criteria for clinical trial reporting. Heart Fail Clin 2011;7:373-384.
9. Lopez L, Colan SD, Frommelt PC, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: A report from the pediatric measurements writing group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiograpr 2010;23:465-495.
10. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. Golzari H, Dawson NV, Speroff T, et al. Prolonged QTc intervals on admission electrocardiograms: Prevalence and correspondence with admission electrolyte abnormalities. Conn Med 2007;71:389-397.
12. Centers for Disease Control and Prevention. BMI Calculator-Pediatric http://www.quesgen.com/BMIPedsCalc.php. Published June 8, 2011. Accessed June 28, 2012.
13. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Children's Cancer study group. Pediatrics 1992;89:942-949.
14. Watts RG, George M. Johnson WH, Jr. Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: A 5-year review at a single pediatric oncology center. Cancer 2012;118:1919-1924.
15. Nousiainen T, Jantunen E, Vanninen E, et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2002;86:1697-1700.
16. Belham M, Kruger A, Mepham S, et al. Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail 2007;9:409-414.
17. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes-a report from the Children's Oncology group. J Clin Oncol 2012;30:1415-1421.
18. Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012;30:1422-1428. Epub September 6, 2011.
19. Postma A, Bink-Boelkens MT, Beaufort-Krol GC, et al. Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 1996;26:230-237.
20. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the childhood cancer survivor study cohort. BMJ 2009;339:b4606.
21. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood cancer survivors of a solid tumor at the institute Gustave Roussy. Br J Cancer 2004;91:37-44.
22. Kremer LC, Van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline induced clinical heart failure in children: A systematic review. Ann Oncology 2002;13:503-512.
23. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the cardiovascular disease task force of the children's oncology group. Pediatrics 2008;121:e387-e396.
24. Ginsberg JP, Goodman P, Leisenring W, et al. Long-term survivors of childhood Ewing sarcoma: A report from the childhood cancer survivor study. JNCI 2010;102:1272-1283.
25. Longhi A, Ferrari S, Tamburini A, et al. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: The Italian sarcoma group experience (1983-2006). Cancer 2012;118:5050-5059.
26. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991;15:1221-1229.
27. Berrak SG, Ewer MS, Jaffe N, et al. Doxorubicin cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 2001;8:611-614.
28. Jurgens H, Bier V, Dunst J, et al. Die GPO cooperativen Ewing-Sarkom Studies CESS 81/86 bericht nach 61/2 Jahren. Klin Padiatr 1988;200:243-252.
29. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol 2002;20:1677-1682.
30. Levitt GA, Dorup I, Sorensen K, et al. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol 2004;124:463-468.
31. Van Dalen EC, van der Pal HJH, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2006;18:CD005008.
32. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukemia; long-term follow-up of a prospective, randomized, multicentre trial. Lancet Oncol 2010;11:950-961.
33. Harake D, Franco VI, Henkel JM, et al. Cardiotoxicity in childhood cancer survivors: Strategies for prevention and management. Future Cardiol 2012;8:647-670.
34. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline toxicity after childhood cancer: A prospective longitudinal study. Cancer 2003;97:1991-1998.
35. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A children's oncology group study. J Clin Oncol 2009;27:2536-2541.
36. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's Sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
37. Andolina J, Dilley K. Anthracycline induced cardiac toxicity more likely in underweight childhood cancer survivors. J Pediatr Hematolol Oncol 2010;32:411-415.
38. Sucak GT, Suyani E, Baysal NA, et al. The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning. Int J Hematol 2012;95:95-101.
39. Murry DJ, Riva L, Poplack DG. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 1998;11:48-51.